Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 466 articles:
HTML format



Single Articles


    April 2021
  1. GERLICH W
    Hepatitis B virus - an anaerobic organism?
    J Hepatol. 2021 Apr 2. pii: S0168-8278(21)00166.
    PubMed    


    March 2021
  2. CRESPO J, Lazarus JV, Iruzubieta P, Garcia F, et al
    Let's leverage SARS-CoV2 vaccination to screen for hepatitis C screening in Spain, in Europe, around the world.
    J Hepatol. 2021 Mar 20. pii: S0168-8278(21)00181.
    PubMed    


  3. DURANTEL D, Dousson CB, Lampertico P
    Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00087.
    PubMed    


  4. ARTRU F, Bou Saleh M, Maggiotto F, Lassailly G, et al
    Erratum to: "IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis".
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00149.
    PubMed    


    February 2021
  5. MARTIN MT, Patel S, Kulik L, Chan C, et al
    Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.
    J Hepatol. 2021 Feb 27. pii: S0168-8278(21)00158.
    PubMed    


  6. INOUE T, Kusumoto S, Iio E, Ogawa S, et al
    Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation.
    J Hepatol. 2021 Feb 26. pii: S0168-8278(21)00151.
    PubMed     Abstract available


  7. GUDD CL, Au L, Triantafyllou E, Shum B, et al
    Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
    J Hepatol. 2021 Feb 22. pii: S0168-8278(21)00108.
    PubMed     Abstract available


  8. CON D, Clayton-Chubb D, Lubel J, Sawhney R, et al
    Dynamics of liver stiffness in chronic hepatitis B patients with concurrent metabolic-associated fatty liver disease.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00113.
    PubMed    


  9. HE Y, Feng D, Hwang S, Mackowiak B, et al
    Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IkappaBzeta target genes in hepatocytes.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00104.
    PubMed     Abstract available


  10. CAPRARU C, Feld JJ
    Remaining challenges in HCV elimination.
    J Hepatol. 2021 Feb 12. pii: S0168-8278(20)33845.
    PubMed    


    January 2021
  11. WING PA, Liu PJ, Harris JM, Magri A, et al
    Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter.
    J Hepatol. 2021 Jan 28. pii: S0168-8278(21)00042.
    PubMed     Abstract available


  12. MARJOT T, Buescher G, Sebode M, Barnes E, et al
    SARS-CoV-2 infection in patients with autoimmune hepatitis.
    J Hepatol. 2021 Jan 26. pii: S0168-8278(21)00033.
    PubMed     Abstract available


  13. DE MARTIN E, Coilly A, Chazouilleres O, Roux O, et al
    Early liver transplantation for corticosteroid non-responders in acute severe autoimmune hepatitis: the SURFASA score.
    J Hepatol. 2021 Jan 24. pii: S0168-8278(21)00041.
    PubMed     Abstract available


  14. HORVATITS T, Wissmann JE, Johne R, Groschup MH, et al
    Hepatitis E virus persists in the ejaculate of chronically infected men.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00025.
    PubMed     Abstract available


  15. RIZZETTO M, Hamid S, Negro F
    The changing scenario of hepatitis D.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00023.
    PubMed     Abstract available


  16. GIACOMELLI A, Pagani G, Conti F, Bassoli C, et al
    Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00009.
    PubMed    


  17. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    PubMed    


    December 2020
  18. BUTI M, Dominguez-Hernandez R, Casado MA
    Impact of the COVID 19 Pandemic on HCV Elimination in Spain.
    J Hepatol. 2020 Dec 20. pii: S0168-8278(20)33891.
    PubMed    


  19. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.
    PubMed    


  20. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    PubMed    


  21. LOHSE AW, Sebode M, Vesterhus M
    Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis".
    J Hepatol. 2020 Dec 9. pii: S0168-8278(20)33818.
    PubMed    


  22. WAHLIN S, Efe C
    Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis.
    J Hepatol. 2020 Dec 9. pii: S0168-8278(20)33628.
    PubMed    


  23. GARCIA-LOPEZ M, Lens S, Pallett LJ, Testoni B, et al
    Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33830.
    PubMed     Abstract available


  24. TANG X, Qi T, Li B, Chen J, et al
    Pre-acute-on-chronic liver failure in hepatitis B-related patients.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33607.
    PubMed    


  25. ZEUZEM S
    Introducing the HCV miniseries.
    J Hepatol. 2020;73:1306.
    PubMed    


  26. BAUMERT TF
    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.
    PubMed    


  27. ZHANG Z, Urban S
    New Insights into Hepatitis D Virus Persistence: the Role of Interferon Response and Implications for Upcoming Novel Therapies.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33819.
    PubMed     Abstract available


  28. NEGRO F
    Residual risk of liver disease after hepatitis C virus eradication.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33827.
    PubMed     Abstract available


    November 2020
  29. KUSHNER T, Reau N
    Changing epidemiology, implications, and recommendations for Hepatitis C in Women of Childbearing Age and During Pregnancy.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33814.
    PubMed     Abstract available


  30. SU F, Weiss NS, Beste LA, Moon AM, et al
    Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33807.
    PubMed     Abstract available


  31. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    PubMed     Abstract available



  32. Reply to: "EASL recommendations on treatment of hepatitis C: Final update of the series - some issues".
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33741.
    PubMed    


  33. DAI CY, Chuang WL, Yu ML
    EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues.
    J Hepatol. 2020 Nov 19. pii: S0168-8278(20)33693.
    PubMed    


  34. WEINFURTNER K, Reddy KR
    Hepatitis C Viremic Organs in Solid Organ Transplantation.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33767.
    PubMed     Abstract available


  35. SUSLOV A, Meier MA, Ketterer S, Wang X, et al
    Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33753.
    PubMed     Abstract available


  36. AQEL B, Wijarnpreecha K, Pungpapong S, Taner CB, et al
    Outcomes following transplantation of HCV-seropositive livers to HCV-seronegative recipients.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33754.
    PubMed     Abstract available


  37. GRETA A, Ilaria M, Domenico FG, Valeria B, et al
    Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33751.
    PubMed     Abstract available


  38. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.
    PubMed    


    October 2020
  39. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    PubMed    


  40. CRESPO J, Diaz-Gonzalez A, Iruzubieta P, Llerena S, et al
    SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33679.
    PubMed    


    September 2020
  41. WEN Z, Feng Y, Yan X
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Sep 29. pii: S0168-8278(20)30491.
    PubMed    


  42. THIMME R
    T cell immunity to hepatitis C virus: lessons for a prophylactic HCV vaccine.
    J Hepatol. 2020 Sep 28. pii: S0168-8278(20)33665.
    PubMed     Abstract available


  43. PAPATHEODORIDIS G, Sypsa V, Lampertico P
    Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33615.
    PubMed    


  44. HOWELL J, Pedrana A, Schroeder SE, Scott N, et al
    A global investment framework for the elimination of hepatitis B.
    J Hepatol. 2020 Sep 21. pii: S0168-8278(20)33625.
    PubMed     Abstract available


  45. ARGIRION I, Mahale P, Pfeiffer RM, Koshiol J, et al
    Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma.
    J Hepatol. 2020 Sep 19. pii: S0168-8278(20)30465.
    PubMed    


  46. ALFAIATE D, Clement S, Goossens N, Negro F, et al
    Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma".
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30543.
    PubMed    


  47. VALERIO H, Alavi M, Law M, Tillakeratne S, et al
    High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)33618.
    PubMed     Abstract available


  48. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
    TEMPORARY REMOVAL: Reduced incidence of hepatitis C in nine villages in rural Egypt: Progress towards national elimination goals.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)33619.
    PubMed     Abstract available


  49. PFEFFERKORN M, Schott T, Bohm S, Deichsel D, et al
    Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)33620.
    PubMed     Abstract available


  50. VERHELST X, Somers N, Geerts A, Degroote H, et al
    Health status of patients with Autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders (Belgium).
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33605.
    PubMed    


  51. HOWELL J, Anderson D, Bloom S, Lubel J, et al
    Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age.
    J Hepatol. 2020 Sep 1. pii: S0168-8278(20)30404.
    PubMed    


  52. VIRZI A, Roca Suarez AA, Lupberger J
    Interferon revisited: Peering behind the lines of antiviral defense.
    J Hepatol. 2020;73:496-498.
    PubMed    


    August 2020
  53. CHARETTE JH, Burak KW, Coffin CS, Congly SE, et al
    Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    J Hepatol. 2020 Aug 31. pii: S0168-8278(20)30458.
    PubMed    


  54. STOCKDALE AJ, Hutin Y, Geretti AM
    Reply to: "Revisiting the estimation of hepatitis D global prevalence".
    J Hepatol. 2020 Aug 27. pii: S0168-8278(20)30444.
    PubMed    


  55. SHIMAKAWA Y, Lemoine M
    Reply to: "Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age".
    J Hepatol. 2020 Aug 25. pii: S0168-8278(20)30463.
    PubMed    


  56. GENESCA J
    Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)30484.
    PubMed    



  57. EASL recommendations on treatment of hepatitis C - Final update of the series.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30548.
    PubMed     Abstract available


  58. MIAO Z, Pan Q
    Revisiting the estimation of hepatitis D global prevalence.
    J Hepatol. 2020 Aug 20. pii: S0168-8278(20)30311.
    PubMed    


  59. CHALOUNI M, Pol S, Sogni P, Fontaine H, et al
    Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    J Hepatol. 2020 Aug 13. pii: S0168-8278(20)30535.
    PubMed     Abstract available


  60. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    PubMed     Abstract available


  61. BLACH S, Kondili LA, Aghemo A, Cai Z, et al
    Impact of COVID-19 on global hepatitis C elimination efforts.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30523.
    PubMed     Abstract available


  62. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    PubMed    


  63. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24).
    J Hepatol. 2020 Aug 1. pii: S0168-8278(20)30455.
    PubMed    


  64. LLEO A, Invernizzi P, Lohse AW, Aghemo A, et al
    Management of patients with autoimmune liver disease during COVID-19 pandemic.
    J Hepatol. 2020;73:453-455.
    PubMed    


    July 2020
  65. PAWLOTSKY JM
    About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus.
    J Hepatol. 2020 Jul 27. pii: S0168-8278(20)30402.
    PubMed    


  66. GALASKI J, Weiler-Normann C, Schakat M, Zachou K, et al
    Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing.
    J Hepatol. 2020 Jul 27. pii: S0168-8278(20)30485.
    PubMed     Abstract available


  67. LAZARUS JV, Picchio CA, Nayagam S, Ratzan S, et al
    Strengthening vaccine confidence during the COVID-19 pandemic: A new opportunity for global hepatitis B virus elimination.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30379.
    PubMed    


  68. FAN R, Papatheodoridis G, Sun J, Innes H, et al
    aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30478.
    PubMed     Abstract available


  69. LOHSE AW, Sebode M, Jorgensen MH, Ytting H, et al
    Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30470.
    PubMed     Abstract available


  70. TAJES SR, Pocurull A, Castillo J, Casanova G, et al
    Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future.
    J Hepatol. 2020 Jul 19. pii: S0168-8278(20)30472.
    PubMed     Abstract available


  71. WEDEMEYER H
    The burden of hepatitis D - defogging the epidemiological horizon.
    J Hepatol. 2020 Jul 16. pii: S0168-8278(20)30440.
    PubMed    


  72. MOUZANNAR K, Liang TJ
    Hepatitis B virus - recent therapeutic advances and challenges to cure.
    J Hepatol. 2020 Jul 15. pii: S0168-8278(20)30227.
    PubMed    


  73. VERNA EC, Akushevich L, Vainorius M, Fried MW, et al
    Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?"
    J Hepatol. 2020 Jul 15. pii: S0168-8278(20)30386.
    PubMed    


  74. LENS S, Miquel M, Mateos-Munoz B, Garcia-Samaniego J, et al
    SARS-CoV2 in patients on antiviral HBV and HCV therapy in Spain.
    J Hepatol. 2020 Jul 13. pii: S0168-8278(20)30460.
    PubMed    


  75. VUERICH M, Harshe R, Frank LA, Mukherjee S, et al
    Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis.
    J Hepatol. 2020 Jul 11. pii: S0168-8278(20)30454.
    PubMed     Abstract available


  76. MEUNIER L, Pageaux GP, Coilly A
    HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30345.
    PubMed    


  77. RENAND A, Cervera-Marzal I, Gil L, Dong C, et al
    Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30453.
    PubMed     Abstract available


  78. ROULOT D, Brichler S, Layese R, BenAbdesselam Z, et al
    Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis Delta.
    J Hepatol. 2020 Jul 4. pii: S0168-8278(20)30441.
    PubMed     Abstract available


  79. CORNBERG M, Pischke S, Muller T, Behrendt P, et al
    Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study.
    J Hepatol. 2020 Jul 2. pii: S0168-8278(20)30312.
    PubMed    


    June 2020
  80. AUDUREAU E, Carrat F, Layese R, Cagnot C, et al
    Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
    J Hepatol. 2020 Jun 29. pii: S0168-8278(20)30394.
    PubMed     Abstract available


  81. HERKEL J, Carambia A, Lohse AW
    Autoimmune hepatitis: Possible triggers, potential treatments.
    J Hepatol. 2020 Jun 26. pii: S0168-8278(20)30174.
    PubMed    


  82. HAMON A, Piquet-Pellorce C, Dimanche-Boitrel MT, Samson M, et al
    Intrahepatocytic necroptosis is dispensable for hepatocyte death in murine immune-mediated hepatitis.
    J Hepatol. 2020 Jun 23. pii: S0168-8278(20)30308.
    PubMed    


  83. FRAGA M, Moradpour D, Artru F, Romailler E, et al
    Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis.
    J Hepatol. 2020 Jun 22. pii: S0168-8278(20)30393.
    PubMed    


  84. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    PubMed     Abstract available


  85. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    PubMed     Abstract available


  86. SHIHA G
    External validation of non-invasive predictors of hepatocellular carcinoma in patients with HCV-related advanced chronic liver disease after oral antivirals.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30196.
    PubMed    


  87. MAK LY, Wan-Hin Hui R, Fung J, Liu F, et al
    Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30361.
    PubMed     Abstract available


  88. MAK LY, Ka-Ho Wong D, Pollicino T, Raimondo G, et al
    Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30357.
    PubMed     Abstract available


  89. NABATCHIKOVA E, Abdurakhmanov D, Rozina T, Nikulkina E, et al
    Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30197.
    PubMed    


  90. GENESCA J
    Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patie
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30237.
    PubMed    


    May 2020
  91. NGUYEN D, Smith D, Vaughan-Jackson A, Magri A, et al
    Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia.
    J Hepatol. 2020 May 26. pii: S0168-8278(20)30348.
    PubMed     Abstract available


  92. CHAN HL, Wong VW, Yip TC, Wong GL, et al
    Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30273.
    PubMed    


  93. SONNEVELD MJ, Brouwer WP, de Man RA
    Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30231.
    PubMed    


  94. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut".
    J Hepatol. 2020;72:1036-1037.
    PubMed    


  95. INNES HA, McDonald SA, Barclay ST, Irving WL, et al
    The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut.
    J Hepatol. 2020;72:1034-1035.
    PubMed    


    April 2020
  96. STOCKDALE AJ, Kreuels B, Henrion MYR, Giorgi E, et al
    The global prevalence of hepatitis D virus infection: systematic review and meta-analysis.
    J Hepatol. 2020 Apr 23. pii: S0168-8278(20)30220.
    PubMed     Abstract available


  97. TOUT I, Loureiro D, Mansouri A, Soumelis V, et al
    Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development.
    J Hepatol. 2020 Apr 22. pii: S0168-8278(20)30225.
    PubMed     Abstract available


  98. ROY A, De A, Singh V
    DAAs and HBV/HCV coinfection: Glimmer of light and a few shades of grey.
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30169.
    PubMed    


  99. YEH ML, Yu ML
    Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey".
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30203.
    PubMed    


  100. KINAST V, Plociennikowska A, Anggakusuma, Bracht T, et al
    C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle.
    J Hepatol. 2020 Apr 12. pii: S0168-8278(20)30209.
    PubMed     Abstract available


  101. LEE HA, Kim BK, Kim SU
    Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy.
    J Hepatol. 2020 Apr 1. pii: S0168-8278(20)30121.
    PubMed    


    March 2020
  102. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    PubMed     Abstract available


  103. SANGIOVANNI A, Alimenti E, Gattai R, Filomia R, et al
    Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30192.
    PubMed     Abstract available


  104. BOON D, Bruce V, Patel EU, Quinn J, et al
    Antibody avidity-based approach to estimate population-level incidence of hepatitis C.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30190.
    PubMed     Abstract available


  105. PAPATHEODORIDIS GV, Lampertico P
    Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".
    J Hepatol. 2020 Mar 27. pii: S0168-8278(20)30173.
    PubMed    


  106. ALFAIATE D, Clement S, Gomes D, Goossens N, et al
    Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
    J Hepatol. 2020 Mar 6. pii: S0168-8278(20)30129.
    PubMed     Abstract available


  107. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(19)30645.
    PubMed    


  108. BUTT AA, Yan P, Shaikh OS, Lo Re V 3rd, et al
    Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30120.
    PubMed     Abstract available


  109. WEICHSELBAUM L, Azouz A, Smolen KK, Das J, et al
    Epigenetic basis for monocyte dysfunction in patients with severe alcoholic hepatitis.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30115.
    PubMed     Abstract available


    February 2020
  110. HAN JW, Sung PS, Hong SH, Lee H, et al
    IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30107.
    PubMed     Abstract available


  111. BERTOLETTI A, Gill US, Kennedy PTF
    Early treatment of chronic hepatitis B in children: Everything to play for?
    J Hepatol. 2020 Feb 14. pii: S0168-8278(19)30720.
    PubMed    


  112. YEH ML, Huang CF, Huang CI, Holmes JA, et al
    Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    J Hepatol. 2020 Feb 13. pii: S0168-8278(20)30074.
    PubMed     Abstract available


  113. LAMPERTICO P, Carrion JA, Curry M, Turnes J, et al
    Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis.
    J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30072.
    PubMed     Abstract available


  114. VANWOLLEGHEM T, Groothuismink ZMA, Kreefft K, Hung M, et al
    Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV.
    J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30071.
    PubMed     Abstract available


  115. FELD JJ
    HCV elimination: It will take a village and then some.
    J Hepatol. 2020 Feb 11. pii: S0168-8278(20)30002.
    PubMed    


  116. SOLOMON SS, McFall AM, Lucas GM, Mehta SH, et al
    Response to: 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' by Seung KJ et al.
    J Hepatol. 2020 Feb 10. pii: S0168-8278(20)30061.
    PubMed    


  117. SKINNER NE, Bailey JR
    Broadly neutralizing antibodies against hepatitis C virus: location, location, location.
    J Hepatol. 2020 Feb 1. pii: S0168-8278(20)30020.
    PubMed    


    January 2020
  118. PAPATHEODORIDIS GV, Sypsa V, Dalekos GN, Yurdaydin C, et al
    Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jan 22. pii: S0168-8278(20)30022.
    PubMed     Abstract available


  119. SPAAN M, Carey I, Bruce M, Shang D, et al
    Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.
    J Hepatol. 2020 Jan 22. pii: S0168-8278(20)30023.
    PubMed     Abstract available


  120. ARTRU F, Saleh MB, Maggiotto F, Lassailly G, et al
    IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis.
    J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30008.
    PubMed     Abstract available


  121. MARCELLIN F, Di Beo V, Aumaitre H, Mora M, et al
    Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).
    J Hepatol. 2020 Jan 7. pii: S0168-8278(19)30646.
    PubMed    


    December 2019
  122. EVON DM, Sarkar S, Amador J, Lok AS, et al
    Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)".
    J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30702.
    PubMed    


  123. CHILDS K, Cannon M, Davis C, Thompson EC, et al
    Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action".
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30697.
    PubMed    


  124. WANG YX, Niklasch M, Liu T, Wang Y, et al
    Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
    J Hepatol. 2019 Dec 18. pii: S0168-8278(19)30722.
    PubMed     Abstract available


  125. HOORNENBORG E, Coyer L, Boyd A, Alfons Achterbergh RC, et al
    High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis.
    J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30719.
    PubMed     Abstract available


  126. CHEUK-FUNG YIP T, Lai-Hung Wong G, Wai-Sun Wong V, Tse YK, et al
    Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
    J Hepatol. 2019 Dec 16. pii: S0168-8278(19)30717.
    PubMed     Abstract available


  127. GUPTA N, Kateera F, Desalegn H, Ocama P, et al
    Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action.
    J Hepatol. 2019 Dec 10. pii: S0168-8278(19)30644.
    PubMed    


  128. AVERHOFF F, Shadaker S, Gamkrelidze A, Kuchuloria T, et al
    Progress and Challenges in a Pioneering Hepatitis C Elimination Program in the Country of Georgia, 2015-2018.
    J Hepatol. 2019 Dec 4. pii: S0168-8278(19)30710.
    PubMed     Abstract available


    November 2019
  129. LIU CH, Lee MH, Lin JW, Liu CJ, et al
    Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals.
    J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30701.
    PubMed     Abstract available


  130. BRASHER NA, Eltahla AA, Underwood A, Boo I, et al
    B cell immunodominance in primary hepatitis C virus infection.
    J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30698.
    PubMed     Abstract available


  131. HAJARIZADEH B, Cunningham EB, Valerio H, Martinello M, et al
    Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
    J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30699.
    PubMed     Abstract available


  132. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
    Educate, Test and Treat Model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
    J Hepatol. 2019 Nov 14. pii: S0168-8278(19)30672.
    PubMed     Abstract available


  133. YU Y, Zhang J, Zhang B, Gao J, et al
    Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea.
    J Hepatol. 2019 Nov 13. pii: S0168-8278(19)30593.
    PubMed    


  134. KIM BK
    Reply to: "Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea".
    J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30614.
    PubMed    


  135. CORNBERG M, Suk-Fong Lok A, Terrault NA, Zoulim F, et al
    Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.
    J Hepatol. 2019 Nov 9. pii: S0168-8278(19)30671.
    PubMed     Abstract available


  136. GILL US, McCarthy NE
    CD4 T cells in hepatitis B virus: "You don't have to be cytotoxic to work here and help".
    J Hepatol. 2019 Nov 7. pii: S0168-8278(19)30610.
    PubMed    


  137. BROWN RS JR, Buti M, Rodrigues L, Chulanov V, et al
    Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
    J Hepatol. 2019 Nov 1. pii: S0168-8278(19)30647.
    PubMed     Abstract available


    October 2019
  138. ALAVI M, Law MG, Dore GJ
    Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis".
    J Hepatol. 2019 Oct 24. pii: S0168-8278(19)30419.
    PubMed    


  139. DORE GJ, Feld JJ, Thompson A, Martinello M, et al
    Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30612.
    PubMed     Abstract available


  140. WILTON J, Samji H, Yu A, Krajden M, et al
    Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis".
    J Hepatol. 2019 Oct 22. pii: S0168-8278(19)30553.
    PubMed    


  141. LAPOINTE-SHAW L, Austin PC, Chung H, Sander B, et al
    Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis.
    J Hepatol. 2019 Oct 21. pii: S0168-8278(19)30387.
    PubMed    


  142. PAWLOTSKY JM
    DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world?
    J Hepatol. 2019 Oct 21. pii: S0168-8278(19)30587.
    PubMed    


  143. PONS M, Rodriguez-Tajes S, Esteban JI, Marino Z, et al
    Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals.
    J Hepatol. 2019 Oct 17. pii: S0168-8278(19)30606.
    PubMed     Abstract available


  144. MACIAS J
    Reply to: "Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes".
    J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30530.
    PubMed    


  145. SUHAS SOLOMON S, Quinn TC, Solomon S, McFall AM, et al
    Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
    J Hepatol. 2019 Oct 8. pii: S0168-8278(19)30588.
    PubMed     Abstract available


  146. LEE JH, Kim KH
    Reply to: "In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients."
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30524.
    PubMed    


  147. VON FELDEN J, Mallet V, Pischke S
    Reply to: "Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014".
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30532.
    PubMed    


  148. VRANCKEN B, Cuypers L, Perez AB, Chueca N, et al
    Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.
    J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30476.
    PubMed    


    September 2019
  149. DESAI R, Singh S, Zalavadia D, Bansal P, et al
    Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014.
    J Hepatol. 2019 Sep 30. pii: S0168-8278(19)30523.
    PubMed    


  150. CHEN HL, Ni YH, Chen PJ, Chang MH, et al
    Antiviral treatment for hepatitis B in infancy: Still an issue for debate.
    J Hepatol. 2019 Sep 30. pii: S0168-8278(19)30465.
    PubMed    


  151. BLACKARD JT, Kwara A, Sherman KE
    In response to identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
    J Hepatol. 2019 Sep 26. pii: S0168-8278(19)30418.
    PubMed    


  152. ZHAO P
    Reply to: "Antiviral treatment for hepatitis B in infancy: Still an issue for debate" and "Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B".
    J Hepatol. 2019 Sep 26. pii: S0168-8278(19)30525.
    PubMed    


  153. LIU LZ, Sun J
    Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B.
    J Hepatol. 2019 Sep 24. pii: S0168-8278(19)30464.
    PubMed    


  154. LING SC, Mogul D
    Treatment of infants with hepatitis B virus: A window of opportunity?
    J Hepatol. 2019 Sep 7. pii: S0168-8278(19)30473.
    PubMed    


  155. WONG GL, Wong VW, Yuen BW, Tse YK, et al
    Risk of hepatitis B surface antigen seroreversion after corticosteroid in patients with previous hepatitis B virus exposure.
    J Hepatol. 2019 Sep 6. pii: S0168-8278(19)30516.
    PubMed     Abstract available


  156. KONIG A, Than TT, Todt D, Yoon SK, et al
    High tolerance of hepatitis B virus to thermal disinfection.
    J Hepatol. 2019 Sep 4. pii: S0168-8278(19)30489.
    PubMed    


    August 2019
  157. NEUMANN-HAEFELIN C
    Paving the way for T cell-based immunotherapies in chronic hepatitis E.
    J Hepatol. 2019 Aug 22. pii: S0168-8278(19)30427.
    PubMed    


  158. CHILDS K, Davis C, Cannon M, Montague S, et al
    Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C.
    J Hepatol. 2019 Aug 7. pii: S0168-8278(19)30468.
    PubMed     Abstract available


  159. DEGASPERI E, Spinetti A, Lombardi A, Landonio S, et al
    Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30461.
    PubMed     Abstract available


  160. ROSSI C, Jeong D, Wong S, McKee G, et al
    Sustained Virologic Response from Interferon-based Hepatitis C regimes IS associated with Reduced risk of Extrahepatic Manifestations.
    J Hepatol. 2019 Aug 6. pii: S0168-8278(19)30462.
    PubMed     Abstract available


  161. JOHANNESSEN A, Aberra H, Desalegn H, Gordien E, et al
    A novel score to select patients for treatment in chronic hepatitis B: Results from a large Ethiopian cohort.
    J Hepatol. 2019 Aug 2. pii: S0168-8278(19)30267.
    PubMed    


  162. KIM BK
    Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction".
    J Hepatol. 2019 Aug 2. pii: S0168-8278(19)30412.
    PubMed    


    July 2019
  163. CHOI J, Lim YS
    Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction.
    J Hepatol. 2019 Jul 24. pii: S0168-8278(19)30385.
    PubMed    


  164. FAURE-DUPUY S, Delphin M, Aillot L, Dimier L, et al
    Hepatitis B Virus-induced modulation of liver macrophage function promotes hepatocyte infection.
    J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30422.
    PubMed     Abstract available


  165. LE BERT N, Salimzadeh L, Gill US, Dutertre CA, et al
    Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.
    J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30424.
    PubMed     Abstract available


  166. DHIMAN RK, Grover GS, Premkumar M, Taneja S, et al
    Decentralized Care with Generic Direct-Acting Antivirals in the Management of Chronic Hepatitis C in a Public Health Care Setting.
    J Hepatol. 2019 Jul 17. pii: S0168-8278(19)30414.
    PubMed     Abstract available


  167. GANE E, Verdon DJ, Brooks AE, Gaggar A, et al
    Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study.
    J Hepatol. 2019 Jul 12. pii: S0168-8278(19)30400.
    PubMed     Abstract available


  168. LOGLIO A, Ferenci P, Colonia Uceda Renteria S, Tham CYL, et al
    Excellent safety and effectiveness of high dose myrcludex-b monotherapy administered for 48 weeks in hdv related compensated cirrhosis: a case report of three patients.
    J Hepatol. 2019 Jul 11. pii: S0168-8278(19)30411.
    PubMed     Abstract available


  169. AREGAY A, Sekyere SO, Deterding K, Port K, et al
    Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
    J Hepatol. 2019 Jul 8. pii: S0168-8278(19)30397.
    PubMed     Abstract available


  170. COMARMOND C, Lorin V, Marques C, Maciejewski-Duval A, et al
    TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30401.
    PubMed     Abstract available


  171. AVERHOFF F, Lazarus JV, Sergeenko D, Colombo M, et al
    Excellence in Viral Hepatitis Elimination - Lessons from Georgia.
    J Hepatol. 2019 Jul 4. pii: S0168-8278(19)30398.
    PubMed    


  172. GOET JC, Floreani A, Verhelst X, Cazzagon N, et al
    Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis.
    J Hepatol. 2019 Jul 3. pii: S0168-8278(19)30384.
    PubMed     Abstract available


    June 2019
  173. CHOLONGITAS E, Papatheodoridis GV
    Liver transplantation using hepatitis B core positive grafts: Which is the optimal antiviral prophylaxis?
    J Hepatol. 2019 Jun 21. pii: S0168-8278(19)30285.
    PubMed    


  174. WONG T, Fung J
    Reply to "Liver transplantation using hepatitis B core positive grafts: Which is the optimal antiviral prophylaxis?"
    J Hepatol. 2019 Jun 20. pii: S0168-8278(19)30350.
    PubMed    


  175. ZHU S, Dong Y, Wang L, Liu W, et al
    Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B.
    J Hepatol. 2019 Jun 19. pii: S0168-8278(19)30356.
    PubMed     Abstract available


  176. BORST K, Graalmann T, Kalinke U
    Reply to: "Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers".
    J Hepatol. 2019 Jun 18. pii: S0168-8278(19)30298.
    PubMed    


  177. KEFALAKES H, Rehermann B
    Inflammation drives an altered phenotype of mucosal-associated invariant T cells in chronic hepatitis D virus infection.
    J Hepatol. 2019 Jun 17. pii: S0168-8278(19)30310.
    PubMed    


  178. LEFERE S, Degroote H, Van Vlierberghe H, Devisscher L, et al
    Unveiling the depletion of Kupffer cells in experimental hepatocarcinogenesis through liver macrophage subtype-specific markers.
    J Hepatol. 2019 Jun 15. pii: S0168-8278(19)30187.
    PubMed    


  179. LLANERAS J, Riveiro-Barciela M, Lens S, Diago M, et al
    Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345.
    PubMed     Abstract available


  180. SOON CF, Behrendt P, Todt D, Manns MP, et al
    Defining Virus-specific CD8+ TCR Repertoires for Therapeutic Regeneration of T Cells against Chronic Hepatitis E.
    J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30349.
    PubMed     Abstract available


  181. BORGIA SM, Dearden J, Yoshida EM, Shafran SD, et al
    Sofosbuvir/Velpatasvir for 12 Weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30343.
    PubMed     Abstract available


  182. SAPENA V, Rios J, Torres F, Marino Z, et al
    Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".
    J Hepatol. 2019 Jun 7. pii: S0168-8278(19)30280.
    PubMed    


  183. YAU T, Hsu C, Kim TY, Choo SP, et al
    Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis.
    J Hepatol. 2019 Jun 6. pii: S0168-8278(19)30300.
    PubMed     Abstract available


  184. WILSON E, Covert E, Hoffmann J, Comstock E, et al
    A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY).
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307.
    PubMed     Abstract available


  185. GOTLIEB N, Moradpour D, Shouval D
    Hepatitis A and E - differences and commonalities.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30297.
    PubMed    


  186. YANG S, Wang L, Pan W, Bayer W, et al
    MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30299.
    PubMed     Abstract available


  187. DUSHEIKO G, Lemoine M
    An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans.
    J Hepatol. 2019;70:1046-1048.
    PubMed    


    May 2019
  188. POL S, Fontaine H, Carrat F
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.
    J Hepatol. 2019 May 23. pii: S0168-8278(19)30186.
    PubMed    


  189. VON FELDEN J, Alric L, Pischke S, Aitken C, et al
    The Burden of Hepatitis E among Patients with Hematological Malignancies: a Retrospective European Cohort Study.
    J Hepatol. 2019 May 17. pii: S0168-8278(19)30290.
    PubMed     Abstract available


  190. EVON DM, Sarkar S, Amador J, Lok AS, et al
    Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30278.
    PubMed     Abstract available


  191. JI F, Yeo YH, Wei MT, Ogawa E, et al
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
    PubMed     Abstract available


  192. ALAVI M, Law MG, Valerio H, Grebely J, et al
    Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    J Hepatol. 2019 May 9. pii: S0168-8278(19)30275.
    PubMed     Abstract available


  193. KONIG A, Yang J, Jo E, Park KHP, et al
    Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
    J Hepatol. 2019 May 8. pii: S0168-8278(19)30271.
    PubMed     Abstract available


  194. ANKCORN M, Gallacher J, Ijaz S, Taha Y, et al
    Convalescent Plasma Therapy for Persistent Hepatitis E Virus Infection.
    J Hepatol. 2019 May 7. pii: S0168-8278(19)30269.
    PubMed    


  195. DIAS J, Hengst J, Parrot T, Leeansyah E, et al
    Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30270.
    PubMed     Abstract available


  196. YURDAYDIN C, Abbas Z, Buti M, Cornberg M, et al
    Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
    J Hepatol. 2019;70:1008-1015.
    PubMed     Abstract available


    April 2019
  197. HONG J, Kushner T, Dieterich D, Garry D, et al
    Reducing mother-to-child transmission of HCV: Is it attainable with a multidisciplinary approach?
    J Hepatol. 2019 Apr 24. pii: S0168-8278(19)30079.
    PubMed    


  198. SCHULZ M, Papp CP, Bock CT, Hofmann J, et al
    Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis E infection in a multivisceral transplanted patient.
    J Hepatol. 2019 Apr 23. pii: S0168-8278(19)30223.
    PubMed    


  199. RAIMONDO G, Locarnini S, Pollicino T, Levrero M, et al
    Update of the statements on biology and clinical impact of occult hepatitis b virus infection.
    J Hepatol. 2019 Apr 17. pii: S0168-8278(19)30259.
    PubMed     Abstract available


  200. WRENSCH F, Keck ZY, Foung SKH, Baumert TF, et al
    Learning from a clinical cohort for HCV vaccine development.
    J Hepatol. 2019 Apr 13. pii: S0168-8278(19)30224.
    PubMed    


  201. MOUNA L, Rossignol E, Tateo M, Coilly A, et al
    Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30136.
    PubMed    


  202. WANDELER G, Mauron E, Atkinson A, Dufour JF, et al
    Incidence of Hepatocellular Carcinoma in HIV/HBV-coinfected Patients on Tenofovir therapy: Relevance for Screening Strategies.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30226.
    PubMed     Abstract available


  203. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    PubMed     Abstract available


  204. KIM SU, Seo YS, Lee HA, Kim MN, et al
    A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30222.
    PubMed     Abstract available


  205. UMUTESI G, Shumbusho F, Kateera F, Serumondo J, et al
    Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa.
    J Hepatol. 2019 Apr 1. pii: S0168-8278(19)30179.
    PubMed    


    March 2019
  206. ABERRA H, Desalegn H, Berhe N, Mekasha B, et al
    The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia.
    J Hepatol. 2019 Mar 23. pii: S0168-8278(19)30116.
    PubMed     Abstract available


  207. WIJAYA RS, Read SA, Schibeci S, Eslam M, et al
    KLRG1+ natural killer cells exert a novel anti-fibrotic function in chronic hepatitis B.
    J Hepatol. 2019 Mar 21. pii: S0168-8278(19)30182.
    PubMed     Abstract available


  208. DENG L, Jiang W, Wang X, Merz A, et al
    Syntenin regulates Hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.
    J Hepatol. 2019 Mar 14. pii: S0168-8278(19)30147.
    PubMed     Abstract available


  209. LIM YS, Gwak GY, Choi J, Lee YS, et al
    Monotherapy with Tenofovir Disoproxil Fumarate for Adefovir-Resistant vs. Entecavir-Resistant Chronic Hepatitis B: a 5-Year clinical trial.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30142.
    PubMed     Abstract available


  210. WONG TC, Fung JY, Yu-Shi Cui T, Lam AH, et al
    Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis.
    J Hepatol. 2019 Mar 11. pii: S0168-8278(19)30139.
    PubMed     Abstract available


  211. FONTAINE H, Alric L, Labreuche J, Legendre B, et al
    Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    J Hepatol. 2019 Mar 9. pii: S0168-8278(19)30020.
    PubMed     Abstract available


  212. WYLES D, Weiland O, Yao B, Weilert F, et al
    Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
    J Hepatol. 2019 Mar 8. pii: S0168-8278(19)30078.
    PubMed    


  213. GILL US, Golden-Mason L
    HCMV jogs the 'memory' of NK cells in HBV.
    J Hepatol. 2019;70:343-345.
    PubMed    


  214. LIU Y, Zeng W, Xi J, Liu H, et al
    Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition.
    J Hepatol. 2019;70:557-559.
    PubMed    


  215. CAVIGLIA GP, Olivero A, Smedile A
    Reply to: "Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition".
    J Hepatol. 2019;70:559-560.
    PubMed    


    February 2019
  216. SAHLI R, Fraga M, Semela D, Moradpour D, et al
    Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland.
    J Hepatol. 2019 Feb 22. pii: S0168-8278(19)30068.
    PubMed    


  217. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30128.
    PubMed     Abstract available


  218. MORGAN FREIMAN J, Wang J, Easterbrook PJ, Robert Horsburgh C, et al
    Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30125.
    PubMed     Abstract available


  219. PARK ES, Lee AR, Kim DH, Lee JH, et al
    Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30120.
    PubMed     Abstract available


  220. DEVARBHAVI H, Asrani SK, Kamath PS
    Reply to: "Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia".
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30066.
    PubMed    


  221. VERGIS N, Atkinson SR, Thursz MR
    The future of therapy for alcoholic hepatitis - Beyond corticosteroids.
    J Hepatol. 2019 Feb 18. pii: S0168-8278(19)30030.
    PubMed    


  222. SINGH SP, Panigrahi S, Mishra D, Khatua CR, et al
    Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia.
    J Hepatol. 2019 Feb 16. pii: S0168-8278(19)30012.
    PubMed    


  223. BANDA DH, Perin PM, Brown RJP, Todt D, et al
    A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30110.
    PubMed     Abstract available


  224. KEMMING J, Reeves E, Nitschke K, Widmeier V, et al
    ERAP1 allotypes impact the epitope repertoire of virus-specific CD8(+) T cell responses in acute hepatitis C virus infection.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30111.
    PubMed     Abstract available


  225. IM GY, Cameron AM, Lucey MR
    Liver transplantation for alcoholic hepatitis.
    J Hepatol. 2019;70:328-334.
    PubMed     Abstract available


  226. MATHURIN P, Thursz M
    Endpoints and patient stratification in clinical trials for alcoholic hepatitis.
    J Hepatol. 2019;70:314-318.
    PubMed     Abstract available


  227. SINGAL AK, Shah VH
    Current trials and novel therapeutic targets for alcoholic hepatitis.
    J Hepatol. 2019;70:305-313.
    PubMed     Abstract available


  228. GAO B, Ahmad MF, Nagy LE, Tsukamoto H, et al
    Inflammatory pathways in alcoholic steatohepatitis.
    J Hepatol. 2019;70:249-259.
    PubMed     Abstract available


    January 2019
  229. BORST K, Graalmann T, Kalinke U
    Reply to: "Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation".
    J Hepatol. 2019 Jan 31. pii: S0168-8278(19)30013.
    PubMed    


  230. SANZ-GARCIA C, Poulsen KL, Bellos D, Wang H, et al
    The non-transcriptional activity of IRF3 modulates hepatic immune cell populations in acute on chronic ethanol administration in mice.
    J Hepatol. 2019 Jan 30. pii: S0168-8278(19)30064.
    PubMed     Abstract available


  231. KESSLER SM, Hoppstadter J, Hosseini K, Laggai S, et al
    Lack of Kupffer cell depletion in diethylnitrosamine-induced hepatic inflammation.
    J Hepatol. 2019 Jan 24. pii: S0168-8278(18)32569.
    PubMed    


  232. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    PubMed     Abstract available


  233. PAPALUCA T, McDonald L, Craigie A, Gibson A, et al
    Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30024.
    PubMed     Abstract available


  234. HSU YC, Yip TC, Ho HJ, Wong VW, et al
    Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32629.
    PubMed    


  235. HSU YC, Yip TC, Wong GL, Wu CY, et al
    Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues".
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32583.
    PubMed    


  236. TSAI JF, Perng DS
    Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32546.
    PubMed    


  237. MARION O, Lhomme S, Del Bello A, Abravanel F, et al
    Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients.
    J Hepatol. 2019;70:206-209.
    PubMed    


    December 2018
  238. DENOLLY S, Granier C, Fontaine N, Pozzetto B, et al
    A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32619.
    PubMed     Abstract available


  239. BARBARA T, Fanny L, Caroline S, Francoise B, et al
    Serum Hepatitis B core-related antigen (HBcrAg) correlates with covalently-closed circular DNA transcriptional activity in chronic hepatitis B patients.
    J Hepatol. 2018 Dec 6. pii: S0168-8278(18)32582.
    PubMed     Abstract available


  240. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    PubMed    


  241. DE MARTIN E, Michot JM, Papouin B, Champiat S, et al
    Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?"
    J Hepatol. 2018 Dec 4. pii: S0168-8278(18)32548.
    PubMed    


    November 2018
  242. RIVEIRO-BARCIELA M, Munoz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, et al
    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?
    J Hepatol. 2018 Nov 28. pii: S0168-8278(18)32504.
    PubMed    


  243. MODIN L, Arshad A, Wilkes B, Benselin J, et al
    Epidemiology and natural history of hepatitis C virus infection among children and young people.
    J Hepatol. 2018 Nov 26. pii: S0168-8278(18)32545.
    PubMed     Abstract available


  244. VAN SEYEN M, Smolders EJ, van Wijngaarden P, Drenth JPH, et al
    Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32492.
    PubMed    


  245. D'AMBROSIO R, Pasulo L, Puoti M, Vinci M, et al
    Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32543.
    PubMed     Abstract available


  246. RASCHE A, Sander AL, Corman VM, Drexler JF, et al
    Evolutionary biology of human hepatitis viruses.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32542.
    PubMed     Abstract available


  247. COSTA R, Todt D, Zapatero-Belinchon F, Schenk C, et al
    SEC14L2, a lipid-binding protein, regulate HCV replication in culture with inter- and intra- genotype variations.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32544.
    PubMed     Abstract available


  248. PHILIPS CA, Augustine P, Padsalgi G, Ahamed R, et al
    Only in the darkness can you see the stars: Severe alcoholic hepatitis and higher grades of acute-on-chronic liver failure.
    J Hepatol. 2018 Nov 20. pii: S0168-8278(18)32456.
    PubMed    


  249. TRIVEDI PJ, Hubscher SG, Heneghan M, Gleeson D, et al
    Grand Round: Autoimmune Hepatitis.
    J Hepatol. 2018 Nov 19. pii: S0168-8278(18)32538.
    PubMed     Abstract available


  250. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    PubMed    


  251. KHERA T, Behrendt P, Bankwitz D, Brown RJP, et al
    Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32527.
    PubMed     Abstract available



  252. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    PubMed    


  253. PHAM LV, Jensen SB, Fahnoe U, Pedersen MS, et al
    HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    J Hepatol. 2018 Nov 2. pii: S0168-8278(18)32515.
    PubMed     Abstract available


    October 2018
  254. JENNY I, Gregory JD, Beth C, Philip C, et al
    Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32494.
    PubMed     Abstract available


  255. YIP TC, Wong GL, Chan HL, Tse YK, et al
    HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32497.
    PubMed     Abstract available


  256. IOANNOU GN
    Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".
    J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445.
    PubMed    


  257. SCHUCH A, Zecher BF, Muller PA, Correia MP, et al
    NK-cell responses are biased towards CD16-mediated effector functions in chronic Hepatitis B virus infection.
    J Hepatol. 2018 Oct 17. pii: S0168-8278(18)32458.
    PubMed     Abstract available


  258. JI F, Yeo YH, He C, Li J, et al
    Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32390.
    PubMed    


  259. NISHIBATAKE KINOSHITA M, Minami T, Tateishi R, Wake T, et al
    Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32454.
    PubMed     Abstract available


  260. DE HAAN LR, van Golen RF
    Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
    J Hepatol. 2018 Oct 4. pii: S0168-8278(18)32382.
    PubMed    


  261. NEWSUM AM, Molenkamp R, van der Meer JT, Rebers SP, et al
    Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission.
    J Hepatol. 2018;69:968-970.
    PubMed    


  262. BERENGUER M, de la Rosa Rodriguez G, Dominguez-Gil B
    Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain.
    J Hepatol. 2018;69:966-968.
    PubMed    


  263. DEUFFIC-BURBAN S, Huneau A, Verleene A, Brouard C, et al
    Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    J Hepatol. 2018;69:785-792.
    PubMed     Abstract available


  264. NGUYEN MH, Ozbay AB, Liou I, Meyer N, et al
    Healthcare Resource Utilization and Costs by Disease Severity in an Insured National Sample of US Patients with Chronic Hepatitis B.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32440.
    PubMed     Abstract available


    September 2018
  265. BELPERIO PS, Shahoumian TA, Loomis TP, Mole LA, et al
    Real-world Effectiveness of Daclatasvir plus Sofosbuvir and Velpatasvir/Sofosbuvir in Hepatitis C Genotype 2 and 3.
    J Hepatol. 2018 Sep 25. pii: S0168-8278(18)32392.
    PubMed     Abstract available


  266. ZHANG T, Hu J, Wang X, Zhao X, et al
    MicroRNA-378 Promotes Hepatic Inflammation and Fibrosis via Modulation of the NFkappaB-TNFalpha Pathway.
    J Hepatol. 2018 Sep 12. pii: S0168-8278(18)32376.
    PubMed     Abstract available


    August 2018
  267. ALY MOKHLES M
    Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land.
    J Hepatol. 2018 Aug 31. pii: S0168-8278(18)32270.
    PubMed    


  268. ZHAO P
    Reply to: "Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land".
    J Hepatol. 2018 Aug 30. pii: S0168-8278(18)32299.
    PubMed    


  269. SERSTE T, Moreno C, Gustot T
    Reply to: "Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis".
    J Hepatol. 2018 Aug 29. pii: S0168-8278(18)32277.
    PubMed    


  270. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis.
    J Hepatol. 2018 Aug 24. pii: S0168-8278(18)32172.
    PubMed    


  271. ROSSI C, Butt Z, Wong S, Buxton J, et al
    Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort.
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32288.
    PubMed     Abstract available


  272. KO C, Chakraborty A, Chou WM, Hasreiter J, et al
    Hepatitis B virus (HBV) genome recycling and de novo secondary infection events maintain stable cccDNA levels.
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32294.
    PubMed     Abstract available


  273. FONTANA RJ, Cirulli ET, Gu J, Kleiner D, et al
    The role of HLA-A *33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32283.
    PubMed     Abstract available


  274. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    PubMed     Abstract available


  275. TERRAULT NA, Pageaux GP
    A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!
    J Hepatol. 2018 Aug 10. pii: S0168-8278(18)32276.
    PubMed    


  276. SARRAZIN C, Cooper CL, Manns MP, Reddy KR, et al
    No Impact of Resistance Associated Substitutions on the Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir for 12 Weeks in HCV DAA-experienced Patients.
    J Hepatol. 2018 Aug 8. pii: S0168-8278(18)32279.
    PubMed     Abstract available


  277. DE MARTIN E, Michot JM, Papouin B, Champiat S, et al
    Reply to: "Mortality due to immunotherapy related hepatitis".
    J Hepatol. 2018 Aug 7. pii: S0168-8278(18)32261.
    PubMed    


  278. BHAVE P, Buckle A, Sandhu S, Sood S, et al
    Mortality due to immunotherapy related hepatitis.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32165.
    PubMed    


  279. LAL BB, Sood V, Khanna R, Alam S, et al
    Immunotolerant children with chronic hepatitis B - To treat or not - The dilemma continues.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32173.
    PubMed    


  280. HERZER K, Gerken G, Kroy D, Tacke F, et al
    Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32179.
    PubMed    


  281. ZHU S, Zhao P
    Reply to: "Immunotolerant children with chronic hepatitis B - To treat or not - The dilemma continues".
    J Hepatol. 2018 Aug 4. pii: S0168-8278(18)32265.
    PubMed    


    July 2018
  282. KIM JH, Kim YD, Lee M, Jun BG, et al
    Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    J Hepatol. 2018 Jul 31. pii: S0168-8278(18)32274.
    PubMed     Abstract available


  283. LAZARUS JV, Pericas JM, Colombo M, Ninburg M, et al
    Viral hepatitis: "E" is for equitable elimination.
    J Hepatol. 2018 Jul 20. pii: S0168-8278(18)32171.
    PubMed    


  284. MCMAHON BJ, Dusheiko G
    Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose?
    J Hepatol. 2018 Jul 11. pii: S0168-8278(18)32126.
    PubMed    


  285. VERMEHREN J, Park JS, Jacobson I, Zeuzem S, et al
    Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
    J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32181.
    PubMed     Abstract available


  286. GRAUPERA I, Lammert F
    Screening is caring: Community-based non-invasive diagnosis and treatment strategies for hepatitis C to reduce liver disease burden.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32125.
    PubMed    


    June 2018
  287. MARSHALL AD, Pawlotsky JM, Lazarus JV, Aghemo A, et al
    The removal of DAA restrictions in Europe - one step closer to eliminating HCV as a major public health threat.
    J Hepatol. 2018 Jun 27. pii: S0168-8278(18)32169.
    PubMed     Abstract available


  288. BELLI LS, Perricone G, Adam R, Cortesi PA, et al
    Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    J Hepatol. 2018 Jun 22. pii: S0168-8278(18)32163.
    PubMed     Abstract available


  289. ROCA SUAREZ AA, Baumert TF, Lupberger J
    Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling.
    J Hepatol. 2018 Jun 21. pii: S0168-8278(18)32118.
    PubMed    


  290. SZABO G
    More than meets the eye: Severe alcoholic hepatitis can present as acute-on-chronic liver failure.
    J Hepatol. 2018 Jun 20. pii: S0168-8278(18)32116.
    PubMed    


  291. FORNS X, Sarrazin C
    Treatment of chronic hepatitis C.
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32019.
    PubMed    


  292. AGARWAL K, Castells L, Mullhaupt B, Rosenberg WMC, et al
    Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32124.
    PubMed     Abstract available


  293. GRONBAEK L, Vilstrup H, Pedersen L, Christensen K, et al
    Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study.
    J Hepatol. 2018 Jun 6. pii: S0168-8278(18)32120.
    PubMed     Abstract available


  294. VAN EIJK JJJ, Cintas P, Jacobs BC, Kamar N, et al
    Reply to: "Association of hepatitis E virus infection and myasthenia gravis: A pilot study".
    J Hepatol. 2018;68:1321-1322.
    PubMed    


    May 2018
  295. OJHA RP, Steyerberg EW
    Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
    J Hepatol. 2018 May 26. pii: S0168-8278(18)31980.
    PubMed    


  296. CHEVALIEZ S, Pawlotsky JM
    New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings.
    J Hepatol. 2018 May 22. pii: S0168-8278(18)32063.
    PubMed     Abstract available


  297. PEERAPHATDIT TB, Simonetto DA, Shah VH
    Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis.
    J Hepatol. 2018 May 21. pii: S0168-8278(18)32058.
    PubMed    


  298. DE MARTIN E, Michot JM, Champiat S, Lambotte O, et al
    Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32030.
    PubMed    


  299. WONG GL, Chan HL, Tse YK, Yip TC, et al
    Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32055.
    PubMed     Abstract available


  300. RINKER F, Zimmer CL, Siederdissen CHZ, Manns MP, et al
    Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32050.
    PubMed     Abstract available


  301. BUGGISCH P, Zeuzem S
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32051.
    PubMed     Abstract available


  302. SINGAL AK, Louvet A, Shah VH, Kamath PS, et al
    Grand Rounds: Alcoholic Hepatitis.
    J Hepatol. 2018 May 10. pii: S0168-8278(18)32047.
    PubMed     Abstract available


  303. GAUCI ML, Baroudjian B, Zeboulon C, Pages C, et al
    Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?
    J Hepatol. 2018 May 7. pii: S0168-8278(18)32025.
    PubMed    


    April 2018
  304. BLOOM S, Kemp W, Nicoll A, Roberts SK, et al
    Liver Stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver related events in hepatitis C.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32023.
    PubMed     Abstract available


  305. MULLHAUPT B, Niederhauser C
    Hepatitis E blood donor screening - More than a mere drop in the ocean?
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32015.
    PubMed    


  306. GROEPPER C, Rufinatscha K, Schroder N, Stindt S, et al
    HCV modifies EGF signalling and upregulates production of CXCR2 ligands: role in inflammation and antiviral immune response.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32013.
    PubMed     Abstract available


  307. WANG L, Gao F, Lin G, Yuan Y, et al
    Association of hepatitis E virus infection and myasthenia gravis: A pilot study.
    J Hepatol. 2018 Apr 19. pii: S0168-8278(18)30133.
    PubMed    


  308. SUSLOV A, Heim MH, Wieland S
    New insights into hepatitis D virus (HDV) induced innate immunity: MDA5 senses HDV replication.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31972.
    PubMed    


  309. BRANDL K, Hartmann P, Jih LJ, Pizzo DP, et al
    Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31973.
    PubMed     Abstract available



  310. EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Apr 9. pii: S0168-8278(18)31968.
    PubMed    


  311. ABDEL-MONEIM A, Aboud A, Abdel-Gabbar M, Zanaty MI, et al
    A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30174.
    PubMed    


  312. AGARWAL K, Brunetto M, Seto WK, Lim YS, et al
    96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    J Hepatol. 2018;68:672-681.
    PubMed     Abstract available


  313. ALAZAWI W, Knolle PA
    Interfering with Kupffer cell replenishment: New insights into liver injury.
    J Hepatol. 2018;68:635-637.
    PubMed    


  314. MEFFERT PJ, Repp KD, Volzke H, Weiss FU, et al
    The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort.
    J Hepatol. 2018;68:858-860.
    PubMed    


  315. NAKAO Y, Hashimoto S, Abiru S, Komori A, et al
    Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?
    J Hepatol. 2018;68:854-855.
    PubMed    


  316. WANG J, Yu Y, Meng Z, Shen C, et al
    Reply to: "HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient".
    J Hepatol. 2018;68:849-851.
    PubMed    


    March 2018

  317. EASL Clinical Practice Guidelines on hepatitis E virus infection.
    J Hepatol. 2018 Mar 30. pii: S0168-8278(18)30155.
    PubMed     Abstract available


  318. HSU YC, Cheuk-Fung Yip T, Ho HJ, Wai-Sun Wong V, et al
    Development of a scoring system to Predict Hepatocellular Carcinoma in Asians on Antivirals for Chronic Hepatitis B.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30170.
    PubMed     Abstract available


  319. ROMANO A, Angeli P, Piovesan S, Noventa F, et al
    "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172.
    PubMed     Abstract available


  320. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    PubMed     Abstract available


  321. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    The long-term prognosis of Alcoholic Hepatitis is poor and independent of disease severity for patients surviving an acute episode (Reply).
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30145.
    PubMed    


  322. ZHANG Z, Filzmayer C, Ni Y, Sultmann H, et al
    Hepatitis D Virus replication is sensed by MDA5 and induces IFN-beta/lambda responses in hepatocytes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30143.
    PubMed     Abstract available


  323. SANDAHL TD, Vilstrup H, Jepsen P
    The long-term prognosis of Alcoholic Hepatitis is poor and independent of disease severity for patients surviving an acute episode.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30147.
    PubMed    


  324. SERSTE T, Cornillie A, Njimi H, Pavesi M, et al
    The prognostic value of Acute-on-Chronic Liver Failure during the course of severe alcoholic hepatitis.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30144.
    PubMed     Abstract available


  325. LUTHER J, Dienstag JL
    Reply: Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30141.
    PubMed    


  326. DELTENRE P, Marot A, Dubois M, Trepo E, et al
    Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30142.
    PubMed    


  327. PETTA S, Adinolfi LE, Fracanzani AL, Rini F, et al
    Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30132.
    PubMed     Abstract available


  328. TOYODA H, Kumada T, Tada T, Mizuno K, et al
    Imaging basis of AFP and WFA(+)M2BP as indicators of the risk of HCC after SVR.
    J Hepatol. 2018;68:606-607.
    PubMed    


  329. CAMMA C, Leandro G
    Direct antiviral agents and risk of HCC: Waiting for Godot.
    J Hepatol. 2018;68:614-616.
    PubMed    


    February 2018
  330. CRESPO G, Trota N, Londono MC, Mauro E, et al
    The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in wait-list composition.
    J Hepatol. 2018 Feb 23. pii: S0168-8278(18)30129.
    PubMed     Abstract available


  331. ZHU S, Zhang H, Dong Y, Wang L, et al
    Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characters: a pilot open-lable randomized study.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30117.
    PubMed     Abstract available


  332. DE CARVALHO DOMINGUEZ SOUZA BF, Konig A, Rasche A, de Oliveira Carneiro I, et al
    A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses.
    J Hepatol. 2018 Feb 8. pii: S0168-8278(18)30079.
    PubMed     Abstract available


  333. PAPATHEODORIDIS GV, Sypsa V, Dalekos G, Yurdaydin C, et al
    8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
    J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30081.
    PubMed     Abstract available


    January 2018
  334. BERG T, Petersen J
    Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2018 Jan 31. pii: S0168-8278(18)30064.
    PubMed    


  335. LEMOINE M, Cooke GS
    The Egyptian hepatitis C programme: a model of HCV treatment intervention?
    J Hepatol. 2018 Jan 30. pii: S0168-8278(18)30068.
    PubMed    


  336. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    PubMed    


  337. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens.
    J Hepatol. 2018 Jan 12. pii: S0168-8278(18)30014.
    PubMed    


  338. LEVADA K, Guldiken N, Zhang X, Vella G, et al
    Hsp72 protects from liver injury via attenuation of hepatocellular death, oxidative stress and JNK-signaling.
    J Hepatol. 2018 Jan 10. pii: S0168-8278(18)30008.
    PubMed     Abstract available


    December 2017
  339. SCHWARZINGER M, Rehm J, Mallet V
    "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 30. pii: S0168-8278(17)32539.
    PubMed    


  340. ALAVI M, Law MG, Dore GJ
    Reply to: "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 29. pii: S0168-8278(17)32538.
    PubMed    


  341. AMPUERO J, Jimeno C, Quiles R, Rosales JM, et al
    Impact of comorbidities on patients outcomes after interferon-free therapy-induced viral eradication in hepatitis.
    J Hepatol. 2017 Dec 27. pii: S0168-8278(17)32535.
    PubMed     Abstract available


  342. SCOTT N, Olafsson S, Gottfreethsson M, Tyrfingsson T, et al
    Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
    J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32528.
    PubMed     Abstract available


  343. LI L, Barry V, Daffis S, Niu C, et al
    Anti-HBV Response to Toll-Like Receptor 7 Agonist GS-9620 is Associated with Intrahepatic Aggregates of T Cells and B Cells.
    J Hepatol. 2017 Dec 14. pii: S0168-8278(17)32490.
    PubMed     Abstract available


  344. SODERHOLM J, Millbourn C, Busch K, Kovamees J, et al
    Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32485.
    PubMed     Abstract available


  345. HELLARD M, Scott N, Sacks Davis R, Pedrana A, et al
    Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32486.
    PubMed    


  346. ASSELAH T, Hassanein T, Waked I, Mansouri A, et al
    Eliminating Hepatitis C within Low Income Countries - the need to cure Genotypes 4, 5, 6.
    J Hepatol. 2017 Dec 8. pii: S0168-8278(17)32482.
    PubMed     Abstract available


  347. ELSHARKAWY A, Raziky ME, Akel WE, Saeed KE, et al
    Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32478.
    PubMed     Abstract available


  348. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed    


  349. HEZODE C, Reau N, Svarovskaia ES, Doehle BP, et al
    Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32476.
    PubMed     Abstract available


  350. ZOULIM F
    Inhibition of hepatitis B virus gene expression: a step towards functional cure.
    J Hepatol. 2017 Dec 4. pii: S0168-8278(17)32480.
    PubMed    


  351. BORST K, Frenz T, Spanier J, Tegtmeyer PK, et al
    Type I interferon receptor-signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis.
    J Hepatol. 2017 Dec 2. pii: S0168-8278(17)32473.
    PubMed     Abstract available


    November 2017
  352. HARTL J, Ehlken H, Sebode M, Peiseler M, et al
    Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
    J Hepatol. 2017 Nov 24. pii: S0168-8278(17)32445.
    PubMed     Abstract available


  353. KUBILIUN M, Patel SJ, Hur C, Dienstag JL, et al
    Early liver transplantation for alcoholic hepatitis: Ready for primetime?
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32452.
    PubMed    


  354. HUPA KL, Deterding K, Port K, Kimmann M, et al
    In Reply to: EASL RECOMMENDATIONS ON TREATMENT OF HEPATITIS C 2016 "Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?"
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32443.
    PubMed    


  355. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    Application of Prognostic Scores in The Stopah Trial: Discriminant Function is no Longer the Optimal Scoring System in Alcoholic Hepatitis.
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32440.
    PubMed     Abstract available


  356. THULUVATH PJ, Kantsevoy S, Thuluvath AJ, Savva Y, et al
    Is Cryptogenic Cirrhosis Different from NASH Cirrhosis?
    J Hepatol. 2017 Nov 18. pii: S0168-8278(17)32441.
    PubMed     Abstract available


  357. LEI Z, Xia Y, Si A, Wang K, et al
    Antiviral Therapy Improves Survival in patients with HBV infection and Intrahepatic Cholangiocarcinoma undergoing Liver Resection.
    J Hepatol. 2017 Nov 16. pii: S0168-8278(17)32438.
    PubMed     Abstract available


  358. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Abstract available


  359. TANG Y, Li H, Li J, Liu Y, et al
    Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil mediated complement activation.
    J Hepatol. 2017 Nov 14. pii: S0168-8278(17)32433.
    PubMed     Abstract available


  360. BUGGISCH P, Vermehren J, Mauss S, Gunther R, et al
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32431.
    PubMed     Abstract available


  361. OSSEMAN Q, Gallucci L, Au S, Cazenave C, et al
    The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32424.
    PubMed     Abstract available


  362. CARRIERI MP, Protopopescu C, Marcellin F, Wittkop L, et al
    The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32406.
    PubMed    


  363. JANSSEN HLA, Brunetto MR, Kim YJ, Ferrari C, et al
    Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32408.
    PubMed     Abstract available


    October 2017
  364. MURCIA O, Carnicer F, Gomez-Escolar L, Miralles C, et al
    Direct antiviral agents against Hepatitis C virus: beneficial or harmful?
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32407.
    PubMed    


  365. POLLMANN J, Gotz JJ, Rupp D, Strauss O, et al
    Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32400.
    PubMed     Abstract available


  366. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Abstract available


  367. LONDONO MC, Forns X, Pascasio JM
    Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32385.
    PubMed    


  368. FRASER H, Martin NK, Brummer-Korvenkontio H, Carrieri P, et al
    Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387.
    PubMed     Abstract available


  369. AZAB M, Shah S, Liu X, Ukken J, et al
    Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32390.
    PubMed    


  370. MUELLER H, Wildum S, Luangsay S, Walther J, et al
    A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393.
    PubMed     Abstract available


  371. BERG T, Petersen J
    Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32345.
    PubMed    


  372. YU Y, Wang J, Li G, Shen C, et al
    Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32346.
    PubMed    


  373. YIP TC, Wong GL, Wong VW, Tse YK, et al
    Durability of Hepatitis B Surface Antigen Seroclearance in Untreated and Nucleos(t)ide Analogue-Treated Patients.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32332.
    PubMed     Abstract available


  374. HALFON P, Scholtes C, Izopet J, Larrat S, et al
    Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    J Hepatol. 2017 Oct 4. pii: S0168-8278(17)32333.
    PubMed     Abstract available


    September 2017
  375. LIEBER SR, Rice JP, Lucey MR, Bataller R, et al
    Controversies in Clinical Trials for Alcoholic Hepatitis.
    J Hepatol. 2017 Sep 28. pii: S0168-8278(17)32325.
    PubMed     Abstract available


  376. DI MAIO VC, Cento V, Aragri M, Paolucci S, et al
    Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?
    J Hepatol. 2017 Sep 20. pii: S0168-8278(17)32288.
    PubMed    


  377. LIU X, Shen JJ, Jung Kim S, Lee YJ, et al
    Necessity of time series analysis and effects of direct-acting antivirals on HCV patients awaiting liver transplantation.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32290.
    PubMed    


  378. ESMAT G, Elbaz T, El Raziky M, Gomaa A, et al
    Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis c genotype-4.
    J Hepatol. 2017 Sep 18. pii: S0168-8278(17)32286.
    PubMed     Abstract available


  379. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed    


  380. CARRIERI MP, Protopopescu C, Marcellin F, Rosellini S, et al
    Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32211.
    PubMed     Abstract available


  381. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed    


  382. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Abstract available


  383. KO HL, Lam TH, Ng H, Toh J, et al
    Identification of Slug and Sox7 as transcriptional repressors binding to the Hepatitis B Virus Core Promoter.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32276.
    PubMed     Abstract available


  384. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed    


  385. LEMON SM, Ott JJ, Van Damme P, Shouval D, et al
    Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32278.
    PubMed     Abstract available


  386. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed    


  387. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Premature ovarian senescence and high miscarriage rate impair fertility in women with hepatitis C virus infection.
    J Hepatol. 2017 Sep 4. pii: S0168-8278(17)32259.
    PubMed     Abstract available


  388. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    PubMed    


  389. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    PubMed    


    August 2017
  390. CALVARUSO V, Craxi A
    HBV recurrence after HCV clearance on DAAs: Sometimes They Come Back.
    J Hepatol. 2017 Aug 29. pii: S0168-8278(17)32256.
    PubMed    


  391. MALLET V, Bruneau J, Zuber J, Alanio C, et al
    Hepatitis E Virus-Induced Primary Cutaneous CD30(+) T cell Lymphoproliferative Disorder.
    J Hepatol. 2017 Aug 28. pii: S0168-8278(17)32250.
    PubMed     Abstract available


  392. KRAMER L, Laurain A, Sultanik P, Tremeaux P, et al
    "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32251.
    PubMed    


  393. GARVEY P, Murphy N, Flanagan P, Brennan A, et al
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249.
    PubMed     Abstract available


  394. PASCASIO JM, Vinaixa C, Ferrer MT, Colmenero J, et al
    Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    J Hepatol. 2017 Aug 22. pii: S0168-8278(17)32215.
    PubMed     Abstract available


  395. MELE D, Mantovani S, Oliviero B, Grossi G, et al
    Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32203.
    PubMed     Abstract available


  396. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed    


  397. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Abstract available


  398. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed    


  399. ZEUZEM S, Dvory-Sobol H, Brainard DM
    No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32191.
    PubMed    


  400. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Response to DAA Therapy in the NHS England Early Access Programme for Rare HCV Subtypes from Low and Middle Income Countries.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32195.
    PubMed    


    July 2017
  401. LAZARUS JV, Wiktor S, Colombo M, Thursz M, et al
    Micro-elimination - A path to global elimination of hepatitis C.
    J Hepatol. 2017 Jul 28. pii: S0168-8278(17)32141.
    PubMed    


  402. SUDA T, Shimakami T, Shirasaki T, Yamashita T, et al
    Reactivation of Hepatitis B Virus from an isolated Anti-HBc positive patient after eradication of Hepatitis C Virus with Direct-acting Antiviral Agents.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32158.
    PubMed    


  403. LOK AS, Zoulim F, Dusheiko G, Ghany MG, et al
    Hepatitis B cure: From discovery to regulatory approval.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32017.
    PubMed     Abstract available


  404. RAJORIYA N, Combet C, Zoulim F, Janssen HLA, et al
    How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach?
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32154.
    PubMed     Abstract available


  405. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Abstract available


  406. DALTON HR, van Eijk JJJ, Cintas P, Madden RG, et al
    Hepatitis E Virus Infection and Acute Non-Traumatic Neurological Injury: A Prospective Multicentre Study.
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32153.
    PubMed     Abstract available


  407. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed    


  408. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Abstract available


    June 2017

  409. Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C.
    J Hepatol. 2017 Jun 29. pii: S0168-8278(17)32129.
    PubMed    


  410. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    PubMed     Abstract available


  411. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed    


  412. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Abstract available


  413. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed    


  414. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed    


  415. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Abstract available


  416. SUSSER S, Dietz J, Schlevogt B, Zuckerman E, et al
    Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    J Hepatol. 2017 Jun 12. pii: S0168-8278(17)32069.
    PubMed     Abstract available


  417. DURIEZ M, Mandouri Y, Lekbaby B, Wang H, et al
    Alternative splicing of Hepatitis B virus: a novel virus/host interaction altering liver immunity.
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32065.
    PubMed     Abstract available


    May 2017
  418. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Abstract available


  419. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed    


  420. TAN-GARCIA A, Wai LE, Zheng D, Ceccarello E, et al
    Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32004.
    PubMed     Abstract available


  421. COLPITTS CC, Baumert TF
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 2017 May 3. pii: S0168-8278(17)30255.
    PubMed    


  422. WENDON, J, Cordoba J, Dhawan A, Larsen FS, et al
    EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure.
    J Hepatol. 2017;66:1047-1081.
    PubMed     Abstract available


  423. MRIDHA AR, Wree A, Robertson AAB, Yeh MM, et al
    NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    J Hepatol. 2017;66:1037-1046.
    PubMed     Abstract available


    April 2017
  424. BANKWITZ D, Doepke M, Hueging K, Weller R, et al
    Maturation of secreted HCV particles by incorporation of secreted apoE protects from antibodies by enhancing infectivity.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30251.
    PubMed     Abstract available


  425. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30249.
    PubMed     Abstract available


  426. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed    


  427. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    PubMed    


  428. LOUVET A, Peck-Radosavljevic M
    Evidence for a role of genetics in alcoholic hepatitis: data from the STOPAH randomized controlled trial.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30210.
    PubMed    


  429. LENGGENHAGER D, Gouttenoire J, Malehmir M, Bawohl M, et al
    Visualization of hepatitis E virus RNA and proteins in the human liver.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30212.
    PubMed     Abstract available


  430. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Abstract available


  431. THONS C, Senff T, Hydes TJ, Manser AR, et al
    HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30213.
    PubMed     Abstract available


  432. VAN SANTEN DK, Van Der Helm JJ, Del Amo J, Meyer L, et al
    Lack of decline in Hepatitis C Virus incidence among HIV-positive men who have sex with men during 1990-2014.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30209.
    PubMed     Abstract available


  433. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Reply to "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30204.
    PubMed    


  434. DORE GJ, Grebely J
    Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30206.
    PubMed    


  435. TUMINO N, Casetti R, Fabbri G, Cimini E, et al
    In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30207.
    PubMed    


  436. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Abstract available


  437. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    PubMed    


  438. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    PubMed     Abstract available


  439. SHIRVANI-DASTGERDI E, Winer BY, Celia-Terrassa A, Kang Y, et al
    Selection of the highly replicative and partially multidrug resistant rtS78T polymerase mutation in two patients with chronic hepatitis B virus infection during tenofovir-entecavir combination therapy.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30198.
    PubMed     Abstract available


  440. TAPPER EB, Sengupta N
    Testing for elevated liver enzymes: central to clinical Hepatology but in need of more data.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30199.
    PubMed    


  441. YU X, Lan P, Hou X, Han Q, et al
    HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1beta production via suppressing the NF-kappaB pathway and ROS production.
    J Hepatol. 2017;66:693-702.
    PubMed     Abstract available


  442. MOHS A, Kuttkat N, Reissing J, Zimmermann HW, et al
    Functional role of CCL5/RANTES for HCC progression during chronic liver disease.
    J Hepatol. 2017;66:743-753.
    PubMed     Abstract available


    March 2017
  443. WESTHAUS S, Deest M, Nguyen AT, Stanke F, et al
    Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.
    J Hepatol. 2017 Mar 28. pii: S0168-8278(17)30184.
    PubMed     Abstract available



  444. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    J Hepatol. 2017 Mar 27. pii: S0168-8278(17)30185.
    PubMed     Abstract available


  445. WELZEL T, Bhardwaj N, Hedskog C, Chodavarapu K, et al
    Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses.
    J Hepatol. 2017 Mar 23. pii: S0168-8278(17)30148.
    PubMed     Abstract available


  446. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    PubMed     Abstract available


  447. BELLI LS, Duvoux C, Berg T, Strazzabosco M, et al
    ELITA consensus statements on use of DAAs in liver transplant candidates and recipients.
    J Hepatol. 2017 Mar 18. pii: S0168-8278(17)30140.
    PubMed     Abstract available


  448. MARTIN NK, Vickerman P, Hickman M
    How to eliminate HCV infection by antiviral treatment.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30142.
    PubMed    


  449. BRUNETTO M, Cornberg M, Chan HL
    How Good Is Hepatitis B Surface Antigen Kinetics Informing Strategy to Stop Antiviral Therapy?
    J Hepatol. 2017 Mar 15. pii: S0168-8278(17)30136.
    PubMed    


  450. TACKE F
    Targeting hepatic macrophages to treat liver diseases.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30125.
    PubMed     Abstract available


    February 2017
  451. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    PubMed     Abstract available


  452. GREBELY J, Swan T, Hickman M, Bruneau J, et al
    Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054.
    PubMed    


  453. PAWLOTSKY JM
    Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30055.
    PubMed    


    January 2017
  454. KLAG T, Dietz J, Werner CR, Schwarz JM, et al
    Hepatitis C "true" late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30006.
    PubMed    


  455. OTT JJ, Horn J, Krause G, Mikolajczyk RT, et al
    Time trends of chronic HBV infection over prior decades - A global analysis.
    J Hepatol. 2017;66:48-54.
    PubMed     Abstract available


    December 2016
  456. VUKOTIC R, Conti F, Andreone P
    Hepatitis C virus eradication in elderly: The challenge worth a long-life elixir?
    J Hepatol. 2016 Dec 21. pii: S0168-8278(16)30745.
    PubMed    


    November 2016
  457. HELLARD M, Pedrana A, Scott N
    Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30680.
    PubMed    


  458. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed    


  459. FALADE-NWULIA O, Sulkowski M
    The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30636.
    PubMed    


    October 2016
  460. ROSS DB, Belperio PS, Chartier M, Backus LI, et al
    Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30557.
    PubMed    


  461. JUSTICE AC, Esserman D, Sarkar S, Levin FL, et al
    Reply to: "Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965".
    J Hepatol. 2016 Oct 4. pii: S0168-8278(16)30558.
    PubMed    


  462. FORNS X, Berg T
    Hepatitis C virus - A teacher of clinical research, cell biology and immunology.
    J Hepatol. 2016;65.
    PubMed    


    September 2016

  463. EASL Recommendations on Treatment of Hepatitis C 2016.
    J Hepatol. 2016 Sep 12. pii: S0168-8278(16)30489.
    PubMed    


    July 2016
  464. BENECHET AP, Iannacone M
    Determinants of hepatic effector CD8+ T cell dynamics.
    J Hepatol. 2016 Jul 13. pii: S0168-8278(16)30335.
    PubMed     Abstract available


  465. NAULT JC, Colombo M
    Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.
    J Hepatol. 2016 Jul 11. pii: S0168-8278(16)30327.
    PubMed    


    May 2016
  466. BILLERBECK E, Mommersteeg MC, Shlomai A, Xiao JW, et al
    Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.
    J Hepatol. 2016 May 2. pii: S0168-8278(16)30166.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: